All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

ONA-XR/Anastrozole Combo Delivers Promising Early Results in HR+ Metastatic Endometrial Cancer

February 8th 2023

Oral progesterone receptor antagonist onapristone extended release in combination with anastrozole induced a confirmed partial response in 2 patients with hormone receptor–positive metastatic endometrial cancer.

Oncolytic Virus/Immunotherapy Combination Delivers Early Survival Benefit in Melanoma

February 8th 2023

Bartosz Chmielowski, MD, discusses the rationale for IGNYTE, the unique mechanism of action of RP1, and how melanoma research is seeking to determine treatments for patients based on their individual resistance mechanisms.

FDA Grants Orphan Drug Designation to Ezurpimtrostat for HCC

February 8th 2023

The FDA has granted an orphan drug designation to ezurpimtrostat, a PPT-1 inhibitor for the treatment of patients with hepatocellular carcinoma.

Updated Orca-T Data Continues to Show Reduced GVHD, Non-Relapse Mortality Rates in Hematologic Cancers

February 8th 2023

Caspian Oliai, MD, discusses how treatment with Orca-T demonstrated a reduction in graft-vs-host disease and non-relapse mortality rates, while also producing higher than expected graft-vs-leukemia and graft-vs-infection effects, in patients with hematologic cancers at more than 1 year of follow-up.

Study Finds Large Gap in Breast Cancer Treatment Recommendations for Patients Aged 70 vs 69

February 8th 2023

Age-based heuristics can lead to large differences in breast cancer treatment based on small differences in chronologic age, according to a new analysis of more than 500,000 patient records.

Neoadjuvant Immunotherapy in Mismatch Repair–Deficient, Early-Stage Colorectal Cancer: The Plot Thickens

February 8th 2023

For decades, resection of the primary tumor, either up front or after neoadjuvant therapy, has remained the standard of care for patients with early-stage (stage I-III) colorectal cancer. Recently, a plethora of data have been published that might change the current surgery-centered paradigm.

Barriers to Confirmatory Trial Enrollment Present Unique Hurdles for Accelerated Approvals

February 8th 2023

Despite the favorable comments and interest in clinical trials, the objective fact is that a distressingly low percentage of patients with cancer, in the range of 2% to 4%, are enrolled in clinical investigative efforts.

Intermittent Dosing Schedule of MDM2 Inhibitor Appears Tolerable in Advanced Cancers

February 8th 2023

The selective small molecule MDM2 inhibitor milademetan administered at an intermittent dosing schedule was tolerable and showed early efficacy in patients with advanced cancers, according to findings from a phase 1 study.

Zanubrutinib Approval Underscores the Importance of Next-Generation BTK Inhibitors in CLL/SLL

February 7th 2023

Lamanna discussed key efficacy and safety data with zanubrutinib from the SEQUOIA and ALPINE trials, the advantages of zanubrutinib compared with previous therapeutic options, and how the approval of the agent will affect the use of next-generation BTK inhibitors in chronic lymphocytic leukemia and small lymphocytic lymphoma .

Immunotherapy Must Become More Precise and Personalized in Lung Cancer

February 7th 2023

To continue making progress in lung cancer treatment, investigators must keep pushing the science in new directions even as immunotherapy becomes more available in earlier lines.

Raising the Bar for KRAS G12C+ Colorectal Cancer Treatment

February 7th 2023

With 2 KRAS G12C inhibitors showing encouraging results in combination with anti-EGFR agents, there is a ray of hope for patients with recurrent colon cancer–a treatment that may offer patients the chance to make it to important milestones.

Launch of AMBLor Test Enables Risk Stratification in Early-Stage Melanoma

February 7th 2023

Avero Diagnostics has launched AMBLor, a first-of-its-kind laboratory test for the identification of early-stage melanoma at low risk of progression.

$1.1 Million Department of Defense Grant Supports Augusta University Research Linking Prostate Cancer and Cardiovascular Diseases

February 7th 2023

Cardiovascular diseases are the follow-up threats many men face after undergoing androgen deprivation therapy, also known as hormonal treatment, for prostate cancer.

Crovalimab Demonstrates Noninferiority to Eculizumab in Phase 3 COMMODORE 2 Trial in PNH

February 7th 2023

Treatment with crovalimab led to disease control through transfusion avoidance and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who have not been previously treated with complement inhibitors.

Frontline Pola-R-CHP, CAR T-Cell Second-line Therapies Are Not Cost-effective in DLBCL

February 7th 2023

An economic analysis showed that neither polatuzumab vedotin-piiq added to standard of care chemotherapy nor CD19-directed chimeric antigen receptor T-cell therapy is likely to be the most cost-effective for patients with diffuse large B-cell lymphoma.

XL092 Plus Atezolizumab Vs Regorafenib Under Investigation in MSS/MSI-Low mCRC

February 7th 2023

The safety and efficacy of a combination regimen comprised of XL092 and atezolizumab is being compared with that of regorafenib monotherapy in patients with microsatellite stable or microsatellite instability–low metastatic colorectal cancer who have progressed on or are intolerant to standard-of-care therapy.

Rising Standards in Regulatory Decisions Highlight Challenges in Drug Development in Lung Cancer

February 6th 2023

If the FDA’s Oncologic Drugs Advisory Committee meeting held on February 10, 2022, was any indication, the days of applying foreign single country or region data to support regulatory approval are gone; instead, regulatory decisions are headed toward the need for regional consistency through multiregional clinical trials, which could help the United States overcome the persistent underrepresentation of racial and ethnic minorities in drug development.

PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC

February 6th 2023

As more agents are evaluated either in addition to or following PD-1/PD-L1 inhibitors, more information may be learned about how best to leverage alternate biomarkers, according to Marina C. Garassino, MD.

Better Understanding of Biomarkers Can Inform Immunotherapy Treatment in SCLC

February 6th 2023

FDA approvals in recent years have started to carve out a role for immunotherapy in the frontline treatment of patients with small cell lung cancer.

RaDaR Assay Predicts Patient Response to Immunotherapy in Stage III Bladder Cancer

February 6th 2023

The RaDaR assay successfully identified the patients with locoregionally advanced urothelial cancer most likely to benefit from treatment with ipilimumab and nivolumab in findings from the second cohort of the phase 1b/2a NABUCCO trial.